Research progress on PD-1/PD-L1 inhibitors in neoadjuvant therapy for esophageal cancer_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

CHEN Liji ¹ , MA Hongmei ^2,3 , ZHANG Shifa ^2,3 , ZHONG Kaize ^2,3 , YANG Dongbao ¹ , SUN Jiuhe ^2,3 , LIU Hongfeng ^2,3 , SONG Ru ^2,3 , ZHANG Jishan ¹ ,  CAI Haibo ^2,3

1. Jining Medical University, Jining, 272000, Shandong, P. R. China;
2. Department of Thoracic Surgery, The First People's Hospital of Jining, Jining, 272000, Shandong, P. R. China;
3. Institute of Thoracic Surgery, Jining Institute of Medical Sciences, Jining, 272000, Shandong, P. R. China;

Corresponding author：

CAI Haibo, Email: 13518670801@163.com

Keywords：

Immunotherapy; esophageal cancer; programmed death protein-1; programmed death ligand-1; inhibitors; neoadjuvant therapy; review

DOI：

10.7507/1007-4848.202409008

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Esophageal cancer is one of the malignant tumors that poses a threat to human health, with both high incidence and malignancy. Currently, surgery following neoadjuvant chemoradiotherapy is the standard treatment for locally advanced esophageal cancer; however, the long-term prognosis remains unsatisfactory. In recent years, inhibitors of programmed death protein-1 (PD-1) and its ligand (programmed death ligand-1, PD-L1) have achieved breakthrough progress in other solid tumors, and research on esophageal cancer is gradually being conducted. With the demonstration of good efficacy of PD-1/PD-L1 inhibitors in the first-line and second-line treatment of advanced unresectable esophageal cancer, their incorporation into neoadjuvant treatment regimens has become a hot topic. Therefore, this article reviews the mechanism of action of PD-1/PD-L1 inhibitors and their application in the neoadjuvant treatment of esophageal cancer.

Citation： CHEN Liji, MA Hongmei, ZHANG Shifa, ZHONG Kaize, YANG Dongbao, SUN Jiuhe, LIU Hongfeng, SONG Ru, ZHANG Jishan, CAI Haibo. Research progress on PD-1/PD-L1 inhibitors in neoadjuvant therapy for esophageal cancer. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2025, 32(5): 714-721. doi: 10.7507/1007-4848.202409008 Copy

1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.	Grigg C, Rizvi NA. PD-L1 biomarker testing for non-small cell lung cancer: Truth or fiction? J Immunother Cancer, 2016, 4: 48.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.	Yan X, Duan H, Ni Y, et al. Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase Ⅱ study (TD-NICE). Int J Surg, 2022, 103: 106680.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.

1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25. Grigg C, Rizvi NA. PD-L1 biomarker testing for non-small cell lung cancer: Truth or fiction? J Immunother Cancer, 2016, 4: 48.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56. Yan X, Duan H, Ni Y, et al. Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase Ⅱ study (TD-NICE). Int J Surg, 2022, 103: 106680.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.

Previous Article
Evaluation progress of the application of staplers in thoracoscopic lung surgery
Next Article
The clinical utility of laboratory tests in patients with aortic dissection

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Research progress on PD-1/PD-L1 inhibitors in neoadjuvant therapy for esophageal cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content